Advanced search
Publication Cover
Cancer Biology & Therapy Volume 13, 2012 - Issue 10
Submit an article Journal homepage
587
Views
16
CrossRef citations to date
0
Altmetric
Research Paper

Silencing of ribonucleotide reductase subunit M1 potentiates the antitumor activity of gemcitabine in resistant cancer cells

Piyanuch Wonganan Division of Pharmaceutics; College of Pharmacy; The University of Texas at Austin; Austin, TX USA
,
Woon-Gye Chung Division of Pharmaceutics; College of Pharmacy; The University of Texas at Austin; Austin, TX USA
,
Saijie Zhu Division of Pharmaceutics; College of Pharmacy; The University of Texas at Austin; Austin, TX USA
,
Kaoru Kiguchi Division of Pharmacology and Toxicology; College of Pharmacy; The University of Texas at Austin; Austin, TX USA
,
John DiGiovanni Division of Pharmacology and Toxicology; College of Pharmacy; The University of Texas at Austin; Austin, TX USA
&
Zhengrong Cui Division of Pharmaceutics; College of Pharmacy; The University of Texas at Austin; Austin, TX USACorrespondence[email protected]
Pages 908-914 | Received 27 Feb 2012, Accepted 22 May 2012, Published online: 01 Aug 2012

Citations (16)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Zhe Chen, Yuanqiang Zheng, Yanchun Shi & Zhengrong Cui. (2018) Overcoming tumor cell chemoresistance using nanoparticles: lysosomes are beneficial for (stearoyl) gemcitabine-incorporated solid lipid nanoparticles. International Journal of Nanomedicine 13, pages 319-336.
Read now
Jimin Shao, Xiyong Liu, Lijun Zhu & Yun Yen. (2013) Targeting ribonucleotide reductase for cancer therapy. Expert Opinion on Therapeutic Targets 17:12, pages 1423-1437.
Read now

Articles from other publishers (14)

Donglin Ding, Alexandra M. Blee, Jianong Zhang, Yunqian Pan, Nicole A. Becker, L. James Maher3rd3rd, Rafael Jimenez, Liguo Wang & Haojie Huang. (2023) Gain-of-function mutant p53 together with ERG proto-oncogene drive prostate cancer by beta-catenin activation and pyrimidine synthesis. Nature Communications 14:1.
Crossref
Zhifei Liu, Liyong Xing, Yanfeng Zhu, Peng Shi & Gang Deng. (2022) Association between TOP2A, RRM1, HER2, ERCC1 expression and response to chemotherapy in patients with non-muscle invasive bladder cancer. Heliyon 8:6, pages e09643.
Crossref
Ami Maruyama, Yuzo Sato, Joji Nakayama, Junko Murai, Takamasa Ishikawa, Tomoyoshi Soga & Hideki Makinoshima. (2021) De novo deoxyribonucleotide biosynthesis regulates cell growth and tumor progression in small-cell lung carcinoma. Scientific Reports 11:1.
Crossref
Enrico Baruffini, Roberta Ruotolo, Franco Bisceglie, Serena Montalbano, Simone Ottonello, Giorgio Pelosi, Annamaria Buschini & Tiziana Lodi. (2020) Mechanistic insights on the mode of action of an antiproliferative thiosemicarbazone-nickel complex revealed by an integrated chemogenomic profiling study. Scientific Reports 10:1.
Crossref
Jiarong Zhou, Linshi Zhang, Huilin Zheng, Wenhao Ge, Yu Huang, Yingcai Yan, Xiaohu Zhou, Wei Zhu, Yang Kong, Yuan Ding & Weilin Wang. (2019) Identification of chemoresistance‐related mRNAs based on gemcitabine‐resistant pancreatic cancer cell lines. Cancer Medicine 9:3, pages 1115-1130.
Crossref
Shruti Rao, Robert A. Beckman, Shahla Riazi, Cinthya S. Yabar, Simina M. Boca, John L. Marshall, Michael J. Pishvaian, Jonathan R. Brody & Subha Madhavan. (2016) Quantification and expert evaluation of evidence for chemopredictive biomarkers to personalize cancer treatment. Oncotarget 8:23, pages 37923-37934.
Crossref
Pei Fan, Li Liu, Yefeng Yin, Zhefu Zhao, Yiyao Zhang, Prince S. Amponsah, Xi Xiao, Nathalie Bauer, Alia Abukiwan, Clifford C. Nwaeburu, Jury Gladkich, Chao Gao, Peter Schemmer, Wolfgang Gross & Ingrid Herr. (2016) MicroRNA-101-3p reverses gemcitabine resistance by inhibition of ribonucleotide reductase M1 in pancreatic cancer. Cancer Letters 373:1, pages 130-137.
Crossref
Yoshimasa Tokunaga, Dage Liu, Jun Nakano, Xia Zhang, Kazuhito Nii, Tetsuhiko Go, Cheng-long Huang & Hiroyasu Yokomise. (2015) Potent effect of adenoviral vector expressing short hairpin RNA targeting ribonucleotide reductase large subunit M1 on cell viability and chemotherapeutic sensitivity to gemcitabine in non-small cell lung cancer cells. European Journal of Cancer 51:16, pages 2480-2489.
Crossref
Y Aye, M Li, M J C Long & R S Weiss. (2014) Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies. Oncogene 34:16, pages 2011-2021.
Crossref
Maria de la Fuente, Marie-Christine Jones, Manuel J. Santander-Ortega, Anja Mirenska, Preethi Marimuthu, Ijeoma Uchegbu & Andreas Schätzlein. (2015) A nano-enabled cancer-specific ITCH RNAi chemotherapy booster for pancreatic cancer. Nanomedicine: Nanotechnology, Biology and Medicine 11:2, pages 369-377.
Crossref
Maria L. Alvarellos, Jatinder Lamba, Katrin Sangkuhl, Caroline F. Thorn, Liewei Wang, Daniel J. Klein, Russ B. Altman & Teri E. Klein. (2014) PharmGKB summary. Pharmacogenetics and Genomics 24:11, pages 564-574.
Crossref
Yufeng ZhuMing QiLijun LaoWei WangLuojie HuaGuang Bai. (2014) Human Equilibrative Nucleoside Transporter 1 Predicts Survival in Patients with Pancreatic Cancer Treated with Gemcitabine: A Meta-Analysis. Genetic Testing and Molecular Biomarkers 18:5, pages 306-312.
Crossref
Xiong Zhang, Fen-Shu Jin, Li-Guo Zhang, Rui-Xue Chen, Jin-Hui Zhao, Yan-Nan Wang, En-Fu Wang & Zhen-Dong Jiang. (2013) Predictive and Prognostic Roles of Ribonucleotide Reductase M1 in Patients with Pancreatic Cancer Treated with Gemcitabine: A Meta-analysis. Asian Pacific Journal of Cancer Prevention 14:7, pages 4261-4265.
Crossref
Qinchuan Wang, Xiyong Liu, Jichun Zhou, Yasheng Huang, Shengjie Zhang, Jianguo Shen, Sofia Loera, Xiaoming Yuan, Wenjun Chen, Mei Jin, Stephen Shibata, Yingbin Liu, Peiguo Chu, Linbo Wang & Yun Yen. (2013) Ribonucleotide Reductase Large Subunit M1 Predicts Poor Survival Due to Modulation of Proliferative and Invasive Ability of Gastric Cancer. PLoS ONE 8:7, pages e70191.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.